LINTEX
920106
LINGOOD
833284
NTGEC
870436
4
CG MED EQUIP.
838810
5
Jiayu Holding
300117
US Stock MarketDetailed Quotes
STRO Sutro Biopharma
- 1.590
- +0.040+2.58%
Close Feb 28 16:00 ET
- 1.522
- -0.068-4.28%
Post 20:01 ET
131.11MMarket Cap-1.03P/E (TTM)
1.598High1.500Low861.46KVolume1.570Open1.550Pre Close1.35MTurnover1.16%Turnover RatioLossP/E (Static)82.46MShares6.13052wk High1.18P/B118.02MFloat Cap1.50052wk Low--Dividend TTM74.23MShs Float28.300Historical High--Div YieldTTM6.34%Amplitude1.500Historical Low1.566Avg Price1Lot Size
About Sutro Biopharma Company
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Company Profile
SymbolSTRO
Company NameSutro Biopharma
Listing DateSep 27, 2018
Issue Price15.00
Founded2003
CEOMr. William J. Newell
MarketNASDAQ
Employees324
Fiscal Year Ends12-31
Address111 Oyster Point Boulevard
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-881-6500
Websitehttp://www.sutrobio.com
Company Executives
- Name
- Position
- Salary
- William J. Newell
- Chief Executive Officer and Director
- 2.13M
- Jane Chung
- President and Chief Operating Officer
- --
- Hans-Peter Gerber
- Chief Scientific Officer
- --
- Dr. Anne Borgman, M.D.
- Chief Medical Officer
- 2.34M
- Venkatesh Srinivasan
- Chief Technical Operations Officer
- --
- Linda A. Fitzpatrick
- Chief People and Communications Officer
- --
- Edward C. Albini
- Chief Financial Officer and Chief Accounting Officer
- --
- Connie L. Matsui
- Chairman of the Board
- 173.11K
- Sukhi Jagpal
- Director
- --
- Heidi Hunter
- Independent Director
- 150.28K
- Joseph M. Lobacki
- Independent Director
- 152.11K
- James P. Panek
- Independent Director
- 138.11K
- Dr. John G. Freund,M.D.
- Independent Director
- 138.11K
- Daniel H. Petree
- Independent Director
- 140.11K
- Dr. Jon Marc Wigginton, M.D.
- Independent Director
- 145.11K
- Dr. Michael Dybbs, PhD
- Independent Director
- 133.11K
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025